1 / 1

Long-term Outcome of AZA Treatment in Autoimmune Rheumatologic Patients

Explore the efficacy and safety of AZA in autoimmune rheumatologic patients, analyzing data from both retrospective and prospective studies. Includes information on FDA, EMA, and EC approval dates, patient enrollment, and data cleaning process.

mickey
Download Presentation

Long-term Outcome of AZA Treatment in Autoimmune Rheumatologic Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Figure 1B. CONSORT Diagram B Retrospectively included patients FDA-approval of AZA:19.05.2004 Compassionate use trt. w. AZA in Austria 24 pts. started on AZA EMA-approval of AZA: 24.10.2008 10 pts. started on AZA EC-approval for AAR 01.02.2009 Start of data entry in eCRF 121 pts. started on AZA Prospectively included patients Data cut-off 20.01.2012 Data cleaning 155 pts. included

More Related